753.55
-1.96 (-0.26%)
| 前收盘价格 | 755.51 |
| 收盘价格 | 757.31 |
| 成交量 | 676,321 |
| 平均成交量 (3个月) | 1,008,519 |
| 市值 | 79,866,830,848 |
| 市盈率 (P/E TTM) | 18.05 |
| 预期市盈率 (P/E Forward) | 16.86 |
| 价格/销量 (P/S) | 5.61 |
| 股市价格/股市净资产 (P/B) | 2.49 |
| 52周波幅 | |
| 利润日期 | 30 Jan 2026 |
| 股息率 (DY TTM) | 0.47% |
| 营业毛利率 | 31.94% |
| 营业利益率 (TTM) | 19.94% |
| 稀释每股收益 (EPS TTM) | 39.36 |
| 季度收入增长率 (YOY) | -3.70% |
| 季度盈利增长率 (YOY) | 12.00% |
| 总债务/股东权益 (D/E MRQ) | 9.20% |
| 流动比率 (MRQ) | 4.93 |
| 营业现金流 (OCF TTM) | 3.95 B |
| 杠杆自由现金流 (LFCF TTM) | 2.08 B |
| 资产报酬率 (ROA TTM) | 6.91% |
| 股东权益报酬率 (ROE TTM) | 15.96% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Regeneron Pharmaceuticals, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.13 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Value |
| 内部持股比例 | 1.89% |
| 机构持股比例 | 91.98% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 1,057.00 (Canaccord Genuity, 40.27%) | 购买 |
| 中 | 834.00 (10.68%) | |
| 低 | 660.00 (UBS, -12.42%) | 保留 |
| 平均值 | 829.30 (10.05%) | |
| 总计 | 6 购买, 4 保留 | |
| 平均价格@调整类型 | 741.09 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 02 Feb 2026 | 818.00 (8.55%) | 购买 | 749.55 |
| 08 Jan 2026 | 820.00 (8.82%) | 购买 | 801.01 | |
| Evercore ISI Group | 22 Jan 2026 | 875.00 (16.12%) | 购买 | 755.51 |
| B of A Securities | 07 Jan 2026 | 860.00 (14.13%) | 购买 | 812.27 |
| Morgan Stanley | 12 Dec 2025 | 768.00 (1.92%) | 保留 | 741.29 |
| 03 Dec 2025 | 767.00 (1.78%) | 保留 | 723.67 | |
| Wells Fargo | 10 Dec 2025 | 745.00 (-1.13%) | 保留 | 726.21 |
| 20 Nov 2025 | 700.00 (-7.11%) | 保留 | 737.00 | |
| BMO Capital | 04 Dec 2025 | 850.00 (12.80%) | 购买 | 722.80 |
| Canaccord Genuity | 04 Dec 2025 | 1,057.00 (40.27%) | 购买 | 722.80 |
| HSBC | 24 Nov 2025 | 890.00 (18.11%) | 购买 | 761.45 |
| Scotiabank | 24 Nov 2025 | 770.00 (2.18%) | 保留 | 761.45 |
| UBS | 07 Nov 2025 | 660.00 (-12.41%) | 保留 | 657.53 |
| 显示更多 | ||||
该时间范围内无数据。
| 股息率 (DY TTM) | 0.47% |
| 1年平均股息收益率 | 0.46% |
| 股息支付比率 | 2.24% |
| 预计下次股息支付 | Mar 2026 |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 20 Nov 2025 | - | 05 Dec 2025 | 0.88 现金 |
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 现金 |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 现金 |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2025 | 3.52 | 4 | 0.46 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合